ABSTRACT
The use of gonadotropin-releasing hormone agonist (GnRHa) has been advocated as a substitute to human chorionic gonadotropin (hCG) for the induction of oocyte maturation and prevention of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) cycles since the late 1980s to early 1990s (1–8). However, the subsequent widespread use of GnRHa for pituitary down-regulation during controlled ovarian stimulation limited its use as an option for triggering oocyte maturation.
